There's nothing generic about this drugmaker's recent performance and continued prospects.

What recent performance says about Teva Pharmaceutical Industries (TEVA) Teva Pharmaceutical Industries (TEVA) has caught investor attention after a mixed run, with a 2.5% decline over the past day ...

Teva Pharmaceutical Industries Limited’s TEVA shares have risen 19.4% in the past month. A key driver of the stock price increase was its mixed second-quarter results announced on July 30. Teva’s ...

Research and development continues to play a central role in the strategy of Teva Pharmaceutical Industries Ltd. Efforts are ...

Teva is undergoing a major business transition, but dividend investors should check out this 6.3% yielding competitor instead ...

Teva Pharmaceutical Industries Limited’s TEVA stock has risen 12.9% in a month. Teva’s stock mainly gained after it announced first-quarter 2025 results on May 7. Teva’s first-quarter results were ...

Teva Pharmaceutical Industries Limited’s TEVA stock has been trading above its 50-day and 200-day simple moving averages (SMAs) since the end of October. It achieved the golden cross in mid-September.

Teva Pharmaceutical Industries Ltd (NYSE:TEVA) stock is trading higher on Wednesday after the company’s first-quarter 2025 financial results. Here are the details. Teva reported revenue of $3.89 ...

Teva Pharmaceutical Industries (NYSE:TEVA) and Sanofi reported positive 44 week data from the RELIEVE UCCD study for ...

Both agencies highlighted Teva's financial discipline, solid liquidity, and return to revenue growth after five years of declines, driven by strength in branded medicines and stabilization in generics ...